文献速递白血病

基于白血病相关免疫表型的个体化微小残留病在急性髓系白血病中的识别及其预后意义

Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance.
PubMed 文献 · Am J Hematol · 2019-02-21

本研究纳入292例成人急性髓系白血病(非M3)患者,建立36种白血病相关免疫表型(LAIP)在正常或再生骨髓中的基线表达水平(<2.00×10⁻⁵至5.71×10⁻⁴),并以此作为个体化阈值评估微小残留病(MRD)。个体化MRD阴性患者生存显著优于0.1%-MRD阴性/个体化MRD阳性或0.1%-MRD阳性患者;在细胞遗传学/分子学低危或中危患者中,个体化MRD状态可区分预后,而0.1%-MRD不能。

要点

  • 建立36种LAIP在正常或再生骨髓中的基线表达水平,作为个体化MRD评估阈值。
  • 个体化MRD阴性患者生存显著优于0.1%-MRD阴性/个体化MRD阳性或0.1%-MRD阳性患者。
  • 在低危或中危患者中,个体化MRD状态可识别预后显著不同的患者,而0.1%-MRD状态不能。

核心结论

  • 基于LAIP的个体化MRD阈值可提高AML预后预测的敏感性,并有助于临床实践中自体造血干细胞移植策略的选择。

研究设计与样本

  • 研究纳入292例成人急性髓系白血病(非M3)患者,鉴定36种LAIP并建立其在正常或再生骨髓中的基线表达水平(<2.00×10⁻⁵至5.71×10⁻⁴),以个体化阈值评估MRD。

主要发现

  • 个体化MRD阴性患者生存显著优于0.1%-MRD阴性/个体化MRD阳性或0.1%-MRD阳性患者。
  • 多因素分析显示,在完全缓解时、第一和第二次巩固疗程后三个时间点中,仅第二次巩固后个体化MRD具有独立预后价值。
  • 在细胞遗传学/分子学低危或中危患者中,个体化MRD状态可识别预后显著不同的患者,而0.1%-MRD状态不能。
  • 在仅接受化疗的低危或中危患者中,个体化MRD阴性者生存良好,与接受异基因造血干细胞移植(ASCT)的患者相当。

关键数值与推荐

  • 36种LAIP的基线表达水平范围为<2.00×10⁻⁵至5.71×10⁻⁴。
  • 以0.1%和个体化阈值分层的MRD状态分别称为0.1%-MRD和个体化MRD。

临床怎么用

  • 作者认为该方法有助于临床实践中ASCT策略的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Based on the leukemia-associated immunophenotypes (LAIPs), minimal residual disease (MRD) related to the outcome can be detected by multiparameter flow cytometry in acute myeloid leukemia (AML) patients. Although 0.1% was commonly used as a cutoff value, measurable MRD or MRD level below 0.1% has also been associated with prognostic significance and more sensitive thresholds (<0.1%) are required for improving AML prognosis prediction. In this study, 292 adult patients diagnosed with AML (non-M3) were enrolled, 36 kinds of LAIPs were identified, and the baseline expression levels in normal or regenerating bone marrows of each kind of LAIP were established, which ranged from <2.00 × 10-5 to 5.71 × 10-4 . The baseline level of each LAIP was considered as the individual threshold for MRD assessment. MRD statuses stratified by 0.1% and individual threshold were termed as 0.1%-MRD and individual-MRD, respectively. The patients of individual-MRDneg showed significantly better survival compared with those of 0.1%-MRDneg /individual-MRDpos or 0.1%-MRDpos . Multivariate analysis showed that when time points of complete remission, post the first and second consolidation courses, were considered, only individual-MRD post second consolidation presented independent prognostic value. Notably, in patients of cytogenetic/molecular low-risk (LR) or intermediate-risk (IR), the individual-MRD status could identify the patients with significantly different outcomes, while 0.1%-MRD status could not. Furthermore, among the patients of the LR or IR group which received chemotherapy only, those with individual-MRDneg status presented favorable survival, which was comparable with that of the patients accepted allogeneic hematopoietic stem cell transplantation (ASCT). This approach is useful in the selection of an ASCT strategy for clinical practice.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Sui JN, Chen QS, Zhang YX, et al. Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance. Am J Hematol. 2019. PMID: 30734356. doi:10.1002/ajh.25431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。